[偏头痛:治疗中有什么新鲜事?]
1Servicio de Neurología Infantil, Hospital de Pediatría Prof. Dr. Juan P Garrahan, Buenos Aires, Argentina.
Medicina
|October 2, 2025
概括
儿科偏头痛管理包括急性和预防性治疗. 新兴疗法看起来有前途,但新的儿科偏头痛治疗方法的证据仍在发展.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是儿童和青少年中普遍存在的头痛疾病.
- 目前的管理策略包括急性和预防性干预.
- 对于儿科患者的新型治疗方法的证据有限.
研究的目的:
- 审查当前关于儿科急性和预防性偏头痛治疗的证据.
- 专注于儿科偏头痛的新兴疗法,包括已批准用于成人和正在儿童中进行研究的疗法.
- 讨论药理和非药理两种策略.
主要方法:
- 对儿科偏头痛疗法的当前证据的文献综述.
- 专注于新兴的治疗方法,如甲胺毒素A,神经调节装置,甲虫,单克隆抗体和5西胺受体激动剂.
- 包括既有和正在研究的治疗方法.
主要成果:
- 托皮拉和普拉诺洛尔在儿科偏头痛中比安慰剂显示出适度的益处.
- 在儿科患者群体中,新型疗法 (如onabotulinumtoxinA,gepants和单克隆抗体) 的证据正在扩大.
- 非药理学策略和神经调节装置也在调查中.
结论:
- 新型儿科偏头痛治疗的证据基础正在增长,但仍然有限.
- 需要进一步的研究,以确定新兴疗法在儿童和青少年中的疗效和安全性.
- 目前的选择,如托皮拉玛和普拉诺洛尔提供适度的好处,突出需要更有效的儿科偏头痛干预措施.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
602
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
602
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
588
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
588
Management of Insomnia
542
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
542
Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245


